Your shopping cart is currently empty

Desisobutyryl-ciclesonide (CIC-AP) is the active metabolite of Ciclesonide with affinity for the glucocorticoid receptor.Ciclesonide is a glucocorticoid with anti-inflammatory activity.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 2 mg | $68 | - | In Stock |
| Description | Desisobutyryl-ciclesonide (CIC-AP) is the active metabolite of Ciclesonide with affinity for the glucocorticoid receptor.Ciclesonide is a glucocorticoid with anti-inflammatory activity. |
| In vitro | Desisobutyryl-ciclesonide showed approximately 120-fold higher binding affinity for the glucocorticoid receptor compared to ciclesonide, and about 12-fold higher than dexamethasone. [1] In Peripheral blood mononuclear cells from atopic asthmatic children sensitized to Phleum pratense (PhlP5), Desisobutyryl-ciclesonide at as low as 0.003 μM already reduced PhlP5-specific proliferation, with complete inhibition at 0.03 μM (vs. 3 μM for ciclesonide). In cultures stimulated with PhlP5, 3 μM Desisobutyryl-ciclesonide significantly reduced the proliferation of PhlP5-specific T-cell blasts and decreased the proportion of interleukin-4 (IL-4) producing cells, indicating suppression of Th2 inflammatory response. [2] |
| In vivo | In a bleomycin-induced bronchopulmonary dysplasia (BPD) neonatal rat model, systemic administration of Desisobutyryl-ciclesonide significantly reduced inflammation with less impact on weight gain, serum IGF-1, and glucose levels compared to dexamethasone, suggesting a safer profile for developmental outcomes. [3] |
| Synonyms | Ciclesonide active principle, CIC-AP |
| Molecular Weight | 470.6 |
| Formula | C28H38O6 |
| Cas No. | 161115-59-9 |
| Smiles | C(CO)(=O)[C@]12[C@]3(C)[C@@](C[C@]1(O[C@H](O2)[C@H]4CCCCC4)[H])([C@]5([C@]([C@@H](O)C3)([C@]6(C)C(CC5)=CC(=O)C=C6)[H])[H])[H] |
| Relative Density. | 1.31g/cm3 |
| Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 80 mg/mL (170 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 3.3 mg/mL (7.01 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.